Compare Stocks: PHAR, CLDX, IMNM, and BEAM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$29.46 +0.6%	$29.45	$17.74 ▼ $38.26	$3.03B	2.22	1.57 million shs	1.27 million shs
CLDX Celldex Therapeutics	$39.37 -0.3%	$38.98	$22.10 ▼ $45.14	$3.10B	0.84	758,933 shs	416,697 shs
IMNM Immunome	$27.16 -0.6%	$24.83	$8.66 ▼ $30.06	$3.10B	2.13	1.12 million shs	795,901 shs
PHAR Pharming Group	$11.46 +2.3%	$12.36	$9.62 ▼ $21.34	$792.72M	0.01	24,388 shs	5,350 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+0.58%	-3.35%	+3.92%	+0.20%	+57.04%
CLDX Celldex Therapeutics	-0.28%	-2.69%	+0.82%	+37.56%	+66.75%
IMNM Immunome	-0.62%	-5.92%	+8.38%	+46.18%	+164.98%
PHAR Pharming Group	+2.32%	-2.72%	+11.70%	-9.16%	-20.19%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$29.46 +0.6%	$29.45	$17.74 ▼ $38.26	$3.03B	2.22	1.57 million shs	1.27 million shs
CLDX Celldex Therapeutics	$39.37 -0.3%	$38.98	$22.10 ▼ $45.14	$3.10B	0.84	758,933 shs	416,697 shs
IMNM Immunome	$27.16 -0.6%	$24.83	$8.66 ▼ $30.06	$3.10B	2.13	1.12 million shs	795,901 shs
PHAR Pharming Group	$11.46 +2.3%	$12.36	$9.62 ▼ $21.34	$792.72M	0.01	24,388 shs	5,350 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+0.58%	-3.35%	+3.92%	+0.20%	+57.04%
CLDX Celldex Therapeutics	-0.28%	-2.69%	+0.82%	+37.56%	+66.75%
IMNM Immunome	-0.62%	-5.92%	+8.38%	+46.18%	+164.98%
PHAR Pharming Group	+2.32%	-2.72%	+11.70%	-9.16%	-20.19%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	2.69	Moderate Buy	$49.00	66.33% Upside
CLDX Celldex Therapeutics	2.85	Moderate Buy	$56.08	42.45% Upside
IMNM Immunome	2.85	Moderate Buy	$34.64	27.53% Upside
PHAR Pharming Group	2.20	Hold	$38.67	237.41% Upside

Current Analyst Ratings Breakdown

Latest PHAR, CLDX, IMNM, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$80.00
8/12/2026	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$31.00 ➝ $35.00
8/12/2026	IMNM Immunome	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
8/10/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/7/2026	PHAR Pharming Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/7/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$40.00 ➝ $46.00
8/7/2026	CLDX Celldex Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $53.00
8/3/2026	PHAR Pharming Group	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
7/31/2026	PHAR Pharming Group	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/30/2026	PHAR Pharming Group	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
7/29/2026	CLDX Celldex Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $72.00

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$139.74M	21.78	N/A	N/A	$10.34 per share	2.85
CLDX Celldex Therapeutics	$1.54M	2,007.61	N/A	N/A	$9.10 per share	4.33
IMNM Immunome	$6.94M	444.50	N/A	N/A	$4.62 per share	5.88
PHAR Pharming Group	$376.13M	2.16	$0.21 per share	55.85	$3.82 per share	3.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$79.99M	-$0.86	N/A	N/A	N/A	-54.75%	-30.71%	-24.07%	11/3/2026 (Estimated)
CLDX Celldex Therapeutics	-$258.76M	-$4.35	N/A	N/A	N/A	N/A	-52.35%	-47.61%	11/9/2026 (Estimated)
IMNM Immunome	-$212.39M	-$2.53	N/A	N/A	N/A	N/A	-50.56%	-46.93%	11/5/2026 (Estimated)
PHAR Pharming Group	$2.85M	$0.12	95.50	38.20	N/A	2.51%	3.40%	1.90%	11/5/2026 (Estimated)

Latest PHAR, CLDX, IMNM, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	IMNM Immunome	-$0.5138	-$0.65	-$0.1362	-$0.65	$0.17 million	N/A
8/6/2026	Q2 2026	CLDX Celldex Therapeutics	-$1.06	-$0.94	+$0.12	-$0.94	$0.74 million	$0.02 million
8/4/2026	Q2 2026	BEAM Beam Therapeutics	-$1.11	-$1.18	-$0.07	-$1.18	$16.37 million	$0.49 million
7/30/2026	Q2 2026	PHAR Pharming Group	$0.0630	$0.02	-$0.0430	$0.02	$99.52 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	0.09	14.57	14.57
CLDX Celldex Therapeutics	N/A	11.82	11.82
IMNM Immunome	N/A	15.08	15.08
PHAR Pharming Group	0.34	3.01	2.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
CLDX Celldex Therapeutics	N/A
IMNM Immunome	44.58%
PHAR Pharming Group	0.03%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.80%
CLDX Celldex Therapeutics	5.20%
IMNM Immunome	7.21%
PHAR Pharming Group	2.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	103.29 million	99.36 million	Optionable
CLDX Celldex Therapeutics	150	78.53 million	74.45 million	Optionable
IMNM Immunome	40	113.58 million	105.39 million	Optionable
PHAR Pharming Group	280	70.78 million	69.31 million	Not Optionable

PHAR, CLDX, IMNM, and BEAM Headlines

Recent News About These Companies

Pharming Group (NASDAQ:PHAR) Shares Gap Up - Should You Buy?

September 2 at 12:19 PM | marketbeat.com

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Large Increase in Short Interest

August 27, 2026 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Shares Gap Up - What's Next?

August 26, 2026 | marketbeat.com

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Up 93.0% in July

August 16, 2026 | marketbeat.com

Pharming introduces Joenja in Japan for adult and paediatric patients with activated PI3K delta syndrome aged 4 and older

August 14, 2026 | pharmabiz.comP

Pharming Group N.V.: Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older

August 13, 2026 | finanznachrichten.de

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Hold" by Brokerages

August 13, 2026 | marketbeat.com

Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older

August 13, 2026 | markets.businessinsider.com

Pharming Group (NASDAQ:PHAR) Shares Gap Down - Should You Sell?

August 12, 2026 | marketbeat.com

Pharming Group (PHAR) Stock Price, Quote, News & History

August 12, 2026 | benzinga.com

Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume - Time to Buy?

August 11, 2026 | marketbeat.com

Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky

August 7, 2026 | prnewswire.com

Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced - Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

August 5, 2026 | tmcnet.com

Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R.

August 5, 2026 | businesswire.com

Pharming Group (NASDAQ:PHAR) Shares Gap Up - Time to Buy?

August 5, 2026 | marketbeat.com

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Pharming Group (PHAR)

August 5, 2026 | globenewswire.com

PHAR Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Pharming Group (PHAR)

August 4, 2026 | tmcnet.com

Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference

August 4, 2026 | finance.yahoo.com

Pharming Group Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Pharming Group (PHAR)

July 31, 2026 | prnewswire.com

Pharming Group N.V. (PHAR) Q2 2026 Earnings Call Transcript

July 30, 2026 | seekingalpha.com

Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader ...

July 30, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PHAR, CLDX, IMNM, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$29.46 +0.17 (+0.58%)

As of 09/3/2026 04:00 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Celldex Therapeutics NASDAQ:CLDX

$39.37 -0.11 (-0.28%)

As of 09/3/2026 04:00 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Immunome NASDAQ:IMNM

$27.16 -0.17 (-0.62%)

As of 09/3/2026 04:00 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Pharming Group NASDAQ:PHAR

$11.46 +0.26 (+2.32%)

As of 09/3/2026 04:00 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHAR, CLDX, IMNM, and BEAM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHAR, CLDX, IMNM, and BEAM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHAR, CLDX, IMNM, and BEAM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PHAR, CLDX, IMNM, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Celldex Therapeutics NASDAQ:CLDX

Immunome NASDAQ:IMNM

Pharming Group NASDAQ:PHAR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHAR, CLDX, IMNM, and BEAM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHAR, CLDX, IMNM, and BEAM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHAR, CLDX, IMNM, and BEAM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PHAR, CLDX, IMNM, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Celldex Therapeutics NASDAQ:CLDX

Immunome NASDAQ:IMNM

Pharming Group NASDAQ:PHAR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools